Research programme: Tat-TAR interaction inhibitors - PTC Therapeutics

Drug Profile

Research programme: Tat-TAR interaction inhibitors - PTC Therapeutics

Latest Information Update: 28 Aug 2007

Price : $50

At a glance

  • Originator PTC Therapeutics
  • Class
  • Mechanism of Action Human immunodeficiency virus tat gene product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 27 Jul 2001 PTC Therapeutics has received a phase I SBIR grant for this programme from the NIH
  • 17 Jan 2001 New profile
  • 17 Jan 2001 Preclinical development for HIV infections treatment in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top